SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Ekso Bionics Holdings

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 9.99% in Ekso Bionics Holdings, Inc. as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed an Amendment No. 1 to Schedule 13G.
• The filing pertains to their beneficial ownership of Common Stock, $0.001 par value per share, in EKSO BIONICS HOLDINGS, INC.
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 2,250,021 shares.
• This ownership represents 9.99% of the issuer's class of securities.
• Armistice Capital, LLC, a Delaware entity, is identified as an investment adviser, while Steven Boyd, a U.S. citizen, is identified as a parent holding company and individual.
• The shares are held with shared voting power and shared dispositive power by both reporting persons.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of ownership, not containing performance or forward-looking statements that would indicate a positive or negative sentiment. It explicitly states the shares were acquired in the ordinary course of business and not for control.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant 9.99% stake by an investment firm like Armistice Capital and its managing member, Steven Boyd, may signal increased institutional interest and confidence in Ekso Bionics Holdings, potentially influencing investor perception and trading activity.

Key Dates

Keywords

Ekso Bionics Holdings, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Investment Adviser, Common Stock, SEC Filing, Institutional Ownership